Related Experiment Video
Updated: Feb 25, 2026
05:52
Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
Published on: October 28, 2022
1.1K
Multicenter study for brain/body hypothermia for hypoxic-ischemic encephalopathy: Changes in HMGB-1
Toshihiko Nakamura1, Hideomi Asanuma2, Satoshi Kusuda3
1Neonatology, Musashino Red Cross Hospital, Sapporo, Japan.
Summary
High-mobility group box-1 (HMGB-1) levels help predict outcomes in neonates with hypoxic-ischemic encephalopathy (HIE). HMGB-1 monitoring is useful for guiding brain/body hypothermia therapy (BHT) necessity and assessing short-term neurological outcomes.
Area of Science:
- Neonatal neurology
- Biomarker research
Background:
- Hypoxic-ischemic encephalopathy (HIE) is a serious condition in newborns.
- Brain/body hypothermia therapy (BHT) is a common treatment for HIE.
- High-mobility group box-1 (HMGB-1) is a potential biomarker for neurological injury.
Purpose of the Study:
- To measure HMGB-1 levels in neonates with HIE undergoing BHT.
- To evaluate the correlation between HMGB-1 levels and treatment outcomes.
- To determine the utility of HMGB-1 in guiding BHT and predicting neurological status.
Main Methods:
- Studied 15 neonates with HIE receiving BHT and 6 not receiving BHT.
- Monitored HMGB-1 levels at 24-hour intervals.
- Utilized MRI to assess neurological outcomes and classify patients based on neurological disorder severity.
Main Results:
- Baseline HMGB-1 was higher in the BHT group compared to the non-BHT group.
- HMGB-1 levels in the BHT group decreased significantly over 2 days, reaching reference ranges.
- Neonates with HIE and neurological disorders showed higher mean HMGB-1 levels.
Conclusions:
- HMGB-1 levels differ based on BHT treatment in HIE.
- Early HMGB-1 measurement may aid in determining BHT necessity.
- HMGB-1 shows potential as a predictor of short-term outcomes in HIE.
